查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1718350

化疗引起的周边神经病变治疗市场按治疗类型、给药途径、患者年龄层、治疗持续时间和最终用户划分——2025 年至 2030 年全球预测

Chemotherapy Induced Peripheral Neuropathy Treatment Market by Treatment Type, Route of Administration, Patient Age Group, Therapy Duration, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

化疗引起的周边神经病变治疗市场在 2024 年的价值为 9.8584 亿美元，预计在 2025 年将成长至 10.6412 亿美元，复合年增长率为 8.21%，到 2030 年将达到 15.8361 亿美元。

主要市场统计数据
基准年2024年 9.8584亿美元
预计2025年 10.6412亿美元
预测年份 2030 1,583,610,000美元
复合年增长率（%） 8.21%

化疗引起的周边神经病变(CIPN) 是影响接受癌症治疗的患者生活品质的重大挑战。这份全面的概述探讨了 CIPN 治疗的现状，并揭示了不断发展的实践和创新研究如何重塑治疗方法。对于药物治疗和非药物治疗的细緻理解的需求从未如此强烈。该报告综合了大量数据和趋势，研究了治疗方法、区域市场动态、主要企业活动和可行的建议，以帮助行业领导者做出策略决策。

由于 CIPN 对患者预后和整体医疗保健成本的直接影响，对其治疗的研究正在不断加强。在这种新形势下，必须同时采用治疗方法和创新治疗方法。新兴治疗方法和可靠的临床数据正在推动更以患者为中心的模式，从而鼓励将创新策略整合到既定的临床方案中。随着肿瘤学领域的不断发展，相关人员必须采取前瞻性的观点，利用最新的市场洞察力来应对治疗设计中的当前挑战和未来机会。

此次聘用为深入研究不断变化的治疗格局、关键细分考虑因素以及决定市场的地理和竞争动态奠定了基础。透过提供从宏观趋势到细微细分因素的广泛分析，本简报可作为策略指南，旨在为决策者提供所需的信息，以改善治疗结果并推动 CIPN 领域的创新。

改变化疗引起的周边神经病变治疗市场

近年来，发生了一些变革，从根本上改变了 CIPN 管理方法。化疗和随后的周边神经病变的紧迫挑战引发了研究和开发的激增，导致向个人化多学科治疗方法的显着转变。从历史上看，CIPN 一直采用有限的标靶治疗进行症状治疗。然而，新的研究成果和技术进步正在整合，以开发更复杂的个人化治疗。

创新的非药物疗法因其促进患者康復的能力而越来越受到认可。针灸、物理治疗和经皮神经电刺激等手动技术作为传统药物治疗措施的可行替代或补充，正在稳步发展。与这些策略同时，人们越来越关注药物治疗，例如抗惊厥药、抗忧郁症和鸦片类药物，这引发了关于其功效、安全性和对患者的适用性的进一步争论。对先进的非药物疗法和优化的药物疗法的双重重视标誌着向整体治疗框架的明显转变。

最近的策略倡议也透过推广针对癌症治疗的神经系统和全身影响的联合治疗来重新定义护理途径。临床医生越来越多地根据患者的独特情况制定治疗计划，而不是仅仅遵循标准化的方案。这种个人化方法依赖药理学研究和调查方法的突破，以确保治疗性介入科学合理并符合以患者为中心的护理模式。

此外，数位健康工具和穿戴式监测系统的进步使临床医生能够即时追踪治疗进展。这种数据主导的洞察力不仅可以提高治疗的精确度，而且还鼓励更积极地应对潜在的副作用。技术创新与临床专业知识的融合显然正在重新定义治疗格局，开启一个以自适应、即时、个人化患者照护为特征的新时代。

CIPN 治疗的进步趋势反映了业界向精准医疗和综合医疗迈进的更广泛趋势。借助新数据和高级分析技术，医疗保健提供者现在能够更好地管理复杂的治疗方法，同时主动管理化疗相关的副作用。这种模式转移不仅改变了患者的治疗结果，也为临床研究和专业实践设定了新的基准。

推动市场差异化的关键细分洞察

详细的細項分析揭示了影响 CIPN 治疗竞争格局和策略前景的几个关键方面。根据治疗类型研究将治疗方法分为非药物治疗和药物治疗两类。在非药物介入中，针灸、物理治疗和经皮神经刺激等治疗方法已变得越来越重要，因为它们能够提供症状管理的替代方法，而没有药物治疗相关的全身副作用。同时，药物介入也在不断发展，特别是针对与 CIPN 相关的潜在神经系统损伤的抗惊厥药、抗忧郁症和鸦片类药物的应用日益广泛。

根据给药途径进一步细分，引入了治疗策略的复杂性和个人化。虽然传统的口服给药因其便利性而继续受到青睐，但肌肉注射和静脉注射等肠外给药方式为需要快速治疗性介入的患者提供了有针对性的给药选择。局部给药也发挥重要作用，它能提供局部缓解，而不会产生广泛的全身性影响，增加了治疗通讯协定的灵活性。对于给药途径的详细考虑凸显了我们致力于提供针对患者的具体方法以优化疗效和安全性的承诺。

此外，患者年龄细分可明确区分成人、老年和儿科患者。这种人口统计细分至关重要，因为与年龄相关的生理差异需要采取客製化方法，考虑到新陈代谢、耐受性和患者的整体復原力。由于患者的状况差异很大，这种细分框架将推动针对特定年龄的治疗方法的发展，并强调更精细的临床指南的必要性。

另一个重要维度是治疗持续时间，将介入措施分为长期治疗和短期治疗。这种细分揭示了个别患者在治疗过程中所需的护理的连续性和强度。策略洞察表明，长期治疗方案对于患有慢性或难治性疾病的患者非常重要，而短期治疗对于急性管理情况有效。了解这些时间细微差别将使相关人员能够更好地分配资源并设计符合患者需求和临床结果的治疗方法。

最后，透过最终使用者设定（例如居家照护、医院或专科诊所）的区分，可以根据护理环境量身定制干预措施。在受控的医院环境中成功实施的治疗方法在应用于居家照护或专科门诊时可能需要进行调整。这种细分洞察可以深刻地指导有关市场定位、资源分配和网路协调的策略决策。这种多层次的细分确保治疗策略不仅满足广泛的临床目标，而且更能满足不同患者群体的不同需求。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 全球癌症发生率上升
      • 提高医疗保健专业人员对化疗引起的周边神经病变的认识
      • 全球政府对肿瘤学研究的资助激增
    • 限制因素
      • 药物开发过程及研发活动高成本
    • 机会
      • 为患有周边神经病变症状的患者开发符合人体工学的可穿戴设备
      • 扩大人工智慧技术在神经病变风险评估预测模型开发的应用
    • 任务
      • 化疗后神经病变的复杂机制
  • 市场区隔分析
    • 治疗类型：抗惊厥药和抗忧郁症，具有稳定神经元活动的双重作用，越来越受到青睐。
    • 最终用户：扩大CIPN在医院的应用
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章化疗引起的周边神经病变治疗市场（依治疗类型）

  • 介绍
  • 非药物治疗
    • 针刺
    • 物理治疗
    • 经皮电刺激
  • 药物治疗
    • 抗惊厥药
    • 抗忧郁症
    • 阿片类药物

第七章化疗引起的周边神经病变治疗市场（依给药途径）

  • 介绍
  • 口服
  • 肠外
    • 肌肉注射
    • 静脉
  • 局部的

第八章化疗引起的周边神经病变治疗市场（依患者年龄层）

  • 介绍
  • 成人
  • 老年人
  • 孩子们

第九章化疗引起的周边神经病变治疗市场（依治疗持续时间）

  • 介绍
  • 长期治疗
  • 短期治疗

第 10 章化疗引起的周边神经病变治疗市场（依最终用户）

  • 介绍
  • 居家照护
  • 医院
  • 专科诊所

11.美洲化疗引起的周边神经病变治疗市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

12. 亚太地区化疗引起的周边神经病变治疗市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

13. 欧洲、中东和非洲化疗引起的周边神经病变治疗市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十四章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • AbbVie Inc.
  • AlgoTherapeutix
  • Amgen Inc.
  • Array BioPharma Inc. by Pfizer Inc.
  • Artelo Biosciences, Inc.
  • Asahi Kasei Corporation
  • Astellas Pharma Inc.
  • Bexion Pharmaceuticals, Inc.
  • Bristol-Myers Squibb Company
  • Eisai Inc.
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Ltd.
  • Grunenthal GmbH
  • Heron Therapeutics, Inc.
  • Ipsen Pharma
  • Kyowa Kirin Co., Ltd.
  • Merck & Co., Inc.
  • Neuralace Medical
  • Novartis AG
  • Regenacy Pharmaceuticals LLC
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Serpin Pharma, LLC
  • Takeda Pharmaceutical Company Limited
  • Veloxis Pharmaceuticals, Inc.
Product Code: MRR-1A1A064C04DA

The Chemotherapy Induced Peripheral Neuropathy Treatment Market was valued at USD 985.84 million in 2024 and is projected to grow to USD 1,064.12 million in 2025, with a CAGR of 8.21%, reaching USD 1,583.61 million by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 985.84 million
Estimated Year [2025] USD 1,064.12 million
Forecast Year [2030] USD 1,583.61 million
CAGR (%) 8.21%

Chemotherapy induced peripheral neuropathy (CIPN) represents a significant challenge that impacts the quality of life for patients undergoing cancer treatments. In this comprehensive summary, we explore the current state of CIPN treatment, underlining how evolving practices and innovative research are reshaping therapeutic approaches. The need for a nuanced understanding of both pharmacological and non-pharmacological treatments has never been greater. This report synthesizes a wealth of data and trends, examining treatment methodologies, regional market dynamics, key company players, and actionable recommendations that support strategic decision-making among industry leaders.

Research into CIPN treatment has intensified, propelled by its direct impact on patient outcomes and overall cost-of-care considerations. In this new landscape, embracing both traditional and breakthrough treatment modalities is essential. Newly emerging therapeutic practices and robust clinical data are driving a more patient-focused paradigm which, in turn, bolsters the integration of innovative strategies into established clinical protocols. As the oncology field continues to evolve, stakeholders must adopt a forward-looking perspective and leverage the latest market insights to address both current challenges and future opportunities in treatment design.

This introduction lays the groundwork for an in-depth examination of the transformative shifts in the treatment landscape, key segmentation insights, and regional as well as corporate competitive dynamics that are defining the market. By presenting an analysis that spans from macro trends to nuanced segmentation factors, this summary serves as a strategic guide designed to empower decision-makers with the intelligence necessary to enhance treatment outcomes and foster innovation in the field of CIPN.

Transformative Shifts in the CIPN Treatment Landscape

Recent years have witnessed transformative shifts that are fundamentally altering the approach to CIPN management. Acute challenges in chemotherapy and subsequent peripheral neuropathy have catalyzed a surge in research and development, resulting in a notable transition towards personalized and multi-disciplinary treatment approaches. Historically, CIPN was managed largely through symptomatic relief with limited targeted therapies. However, the integration of emerging research findings and technological advancements has led to the development of more intricately tailored interventions.

Innovative non-pharmacological treatments have become increasingly recognized for their ability to enhance patient recovery. Techniques such as acupuncture, physical therapy, and transcutaneous electrical nerve stimulation are steadily gaining ground as viable alternatives or complements to conventional pharmacological measures. Alongside these strategies, a refined focus on pharmacological treatments including anticonvulsants, antidepressants, and opioids has stimulated further debate on efficacy, safety, and patient suitability. The dual emphasis on advanced non-drug modalities and optimized drug regimens marks a clear shift towards a holistic treatment framework.

Recent strategic initiatives have also redefined care pathways by promoting multi-modal therapies that address both the neurological and systemic implications of cancer treatments. Clinicians are increasingly tailoring treatment plans based on a patient's unique profile rather than adhering solely to a standardized protocol. This individualized approach draws on breakthroughs in pharmacological research as well as rehabilitative practices, ensuring that therapeutic interventions are both scientifically sound and aligned with patient-centric care models.

Furthermore, the evolution of digital health tools and wearable monitoring systems is enabling clinicians to track treatment progress in real time. This data-driven insight not only enhances therapeutic precision but also fosters a more proactive engagement with potential side effects. The blend of technological innovation with clinical expertise is clearly redefining the treatment landscape and heralding a new era marked by adaptive, real-time, and individualized patient care.

The forward momentum in CIPN treatment reflects a broader industry trend towards precision medicine and integrated care. Empowered by emerging data and advanced analytics, healthcare providers are now better positioned to navigate the complexities of treatment regimens while proactively addressing the adverse effects associated with chemotherapy. This paradigm shift is not only transforming patient outcomes, but also setting new benchmarks in clinical research and professional practice.

Key Segmentation Insights Driving Market Differentiation

An in-depth segmentation analysis reveals several critical dimensions that are shaping the competitive and strategic landscape of CIPN treatment. The investigation based on treatment type distinguishes approaches into non-pharmacological and pharmacological categories. Within non-pharmacological interventions, modalities such as acupuncture, physical therapy, and transcutaneous electrical nerve stimulation demonstrate growing prominence due to their ability to offer alternative avenues for symptom management without the systemic side effects often associated with drug treatments. In parallel, pharmacological interventions continue to evolve, particularly with the increasing adoption of anticonvulsants, antidepressants, and opioids that target the underlying neurological disruptions associated with CIPN.

Further segmentation based on the route of administration introduces an added layer of complexity and personalization in treatment strategies. Traditional oral delivery methods continue to be favored for their convenience, while parenteral routes, including intramuscular and intravenous administration, provide targeted delivery options for patients requiring swift therapeutic intervention. Topical applications also play a vital role by offering localized relief without a broad systemic impact, thereby enhancing the versatility of treatment protocols. This detailed exploration of administration routes underscores the commitment to delivering patient-specific methods that optimize both efficacy and safety.

In addition, the segmentation based on patient age group illustrates a distinct differentiation among adults, geriatrics, and pediatrics. Such demographic segmentation is essential since age-related physiological differences necessitate customized approaches that account for metabolism, tolerance, and overall patient resilience. As patient profiles vary widely, this segmentation framework encourages the development of age-appropriate therapies and highlights the need for more refined clinical guidelines.

Another key dimension is therapy duration, which categorizes interventions into long-term and short-term therapies. This segmentation dimension offers clarity on the sustainability and intensity of care that individual patients may require over the course of their treatment journeys. Strategic insights reveal that long-term therapy solutions are crucial for patients with chronic or refractory symptoms, while short-term therapies are effective in acute management scenarios. By understanding these temporal nuances, stakeholders can better allocate resources and design treatment regimens that align with patient needs and clinical outcomes.

Lastly, differentiation based on the end-user setting, which encompasses home care settings, hospitals, and specialty clinics, allows for the customization of interventions based on the care environment. Treatments that are successfully delivered in a controlled hospital environment may require adjustments when adapted for home care or specialized outpatient clinics. These segmentation insights deeply inform strategic decisions related to market positioning, resource allocation, and network collaborations. Collectively, this layered segmentation approach ensures that treatment strategies not only meet broad clinical objectives but are also finely tuned to the diverse needs of a heterogeneous patient population.

Based on Treatment Type, market is studied across Non-Pharmacological Treatments and Pharmacological Treatments. The Non-Pharmacological Treatments is further studied across Acupuncture, Physical Therapy, and Transcutaneous Electrical Nerve Stimulation. The Pharmacological Treatments is further studied across Anticonvulsants, Antidepressants, and Opioids.

Based on Route of Administration, market is studied across Oral, Parenteral, and Topical. The Parenteral is further studied across Intramuscular and Intravenous.

Based on Patient Age Group, market is studied across Adults, Geriatrics, and Pediatrics.

Based on Therapy Duration, market is studied across Long-Term Therapy and Short-Term Therapy.

Based on End-User, market is studied across Home Care Settings, Hospitals, and Specialty Clinics.

Regional Insights: Market Trends Across Key Geographies

An examination of the global landscape reveals that regional trends are central to understanding the evolving market dynamics in CIPN treatment. In the Americas, robust healthcare infrastructure and active investment in cutting-edge research form the bedrock of patient care innovation, driving a substantial uptake of both pharmacological and non-pharmacological treatments. The region's commitment to integrating novel clinical interventions with traditional treatment paradigms has set a benchmark in patient-centered care.

Across Europe, the Middle East and Africa, market dynamics are deeply influenced by ongoing regulatory reforms and increasing investments in medical research. The collaboration between regional academic institutions and healthcare providers is fostering a progressive environment that supports innovative clinical practices. The emphasis on comprehensive patient management through diversified therapeutic channels, along with the modernization of healthcare delivery systems, is markedly impacting clinical outcomes.

Asia-Pacific continues to emerge as a pivotal growth driver with a strong focus on rapid technological adoption and customized healthcare solutions. Increasing public and private investments in state-of-the-art medical infrastructure are catalyzing the development of advanced treatment practices that cater to the unique needs of its diverse population. Market trends in this region underscore a significant commitment to research, as well as the integration of digital health solutions, which is facilitating a seamless blend of traditional and innovative treatment methodologies.

The regional analysis elucidates the need for localized strategies that account for both economic and cultural factors. Each geographic zone offers distinct opportunities and challenges, thereby necessitating tailored approaches that respect local market conditions while leveraging global clinical insights. Industry stakeholders can draw on these regional insights to optimize growth strategies, enhance clinical collaborations, and ultimately, advance the overall standard of care in CIPN treatment.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Competitive Landscape: Evaluating Key Industry Players

Within the competitive landscape, several key companies have emerged as frontrunners in CIPN treatment innovation. These industry leaders, including AbbVie Inc., AlgoTherapeutix, Amgen Inc., Array BioPharma Inc. by Pfizer Inc., Artelo Biosciences, Inc., and Asahi Kasei Corporation, have been instrumental in propelling the research, development, and commercialization of breakthrough therapeutic solutions. Further contributions come from Astellas Pharma Inc., Bexion Pharmaceuticals, Inc., Bristol-Myers Squibb Company, and Eisai Inc., all of which have demonstrated a steadfast commitment to advancing clinical care in this arena.

Other notable players such as F. Hoffmann-La Roche Ltd and GlaxoSmithKline PLC have leveraged extensive research and robust global networks to introduce both innovative drug compounds and supportive non-pharmacological interventions. The strategic initiatives pursued by Glenmark Pharmaceuticals Ltd., Grunenthal GmbH, and Heron Therapeutics, Inc. have provided additional momentum to the market by focusing on patient-centric treatment design and precision medicine approaches. Ipsen Pharma, Kyowa Kirin Co., Ltd., and Merck & Co., Inc. also play pivotal roles, leveraging cutting-edge research to enhance the efficacy of existing treatment paradigms.

Contributions from Neuralace Medical, Novartis AG, Regenacy Pharmaceuticals LLC, and Regeneron Pharmaceuticals, Inc. further underscore the importance of cross-collaborative efforts in addressing complex clinical challenges. Leading international pharmaceutical companies such as Sanofi S.A., Serpin Pharma, LLC, Takeda Pharmaceutical Company Limited, and Veloxis Pharmaceuticals, Inc. are also key players, with their rigorous research and adaptive clinical strategies helping to shape the future of CIPN treatment. The strategic interplay between these companies is fostering a dynamic ecosystem that continuously refines treatment protocols, enhances patient outcomes, and promotes sustainable clinical innovation across the global market.

The report delves into recent significant developments in the Chemotherapy Induced Peripheral Neuropathy Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AlgoTherapeutix, Amgen Inc., Array BioPharma Inc. by Pfizer Inc., Artelo Biosciences, Inc., Asahi Kasei Corporation, Astellas Pharma Inc., Bexion Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Eisai Inc., F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Grunenthal GmbH, Heron Therapeutics, Inc., Ipsen Pharma, Kyowa Kirin Co., Ltd., Merck & Co., Inc., Neuralace Medical, Novartis AG, Regenacy Pharmaceuticals LLC, Regeneron Pharmaceuticals, Inc., Sanofi S.A., Serpin Pharma, LLC, Takeda Pharmaceutical Company Limited, and Veloxis Pharmaceuticals, Inc.. Actionable Recommendations for Industry Leaders

Leaders in the healthcare and pharmaceutical sectors are advised to adopt a multi-faceted strategic approach to navigate the evolving CIPN treatment landscape effectively. One recommendation is to invest in robust research and development initiatives that blend groundbreaking clinical trials with real-world evidence. By supporting translational research, organizations can bridge the gap between innovative theory and practical application, thereby ensuring that novel therapies are both effective and accessible.

Another key recommendation is to foster strong partnerships between academic institutions, research organizations, and clinical practitioners. Collaborative efforts that unite diverse areas of expertise can provide the synergies necessary to propel the development of both pharmacological and non-pharmacological treatment options. Furthermore, digitization and advanced data analytics should be embraced to facilitate patient-specific treatment planning, monitor outcomes more accurately, and drive continuous process improvements across the care continuum.

Industry leaders should also consider adopting flexible regulatory strategies that allow for quicker adaptation to new clinical data and technological advancements. Proactive engagement with regulatory bodies can smooth the path to market for emerging therapies, ensuring that groundbreaking treatments reach patients with minimal delays. Additionally, an emphasis on market education and awareness, through initiatives that communicate the benefits and limitations of different treatment modalities, can help healthcare providers integrate new approaches into mainstream clinical practice more seamlessly.

Finally, it is critical to allocate sufficient resources towards enhancing cross-functional expertise within organizations. By cultivating teams that are well-versed in both clinical and commercial aspects, companies can better anticipate market shifts, tailor strategies to evolving patient needs, and ultimately drive long-term value creation. Industry leaders are encouraged to evaluate their current portfolios, reassess strategic priorities, and invest in innovation centers that can serve as incubators for next-generation therapeutic solutions.

Comprehensive Summary and Forward-Looking Perspective

In summary, the analysis presented in this report highlights the multifaceted and evolving nature of CIPN treatment. From the integration of novel non-pharmacological techniques to the advancement of pharmacological interventions, the landscape is clearly defined by a dynamic interplay between innovation and patient-centered care. Detailed segmentation analysis across treatment types, routes of administration, patient age groups, therapy duration, and end-user settings articulates how personalized and adaptable care models are essential for addressing the challenges inherent in managing chemotherapy induced peripheral neuropathy.

Regional insights further cement the role of localized strategies in maximizing treatment efficacy across distinct geographic markets such as the Americas, Europe, Middle East & Africa, and Asia-Pacific. These regions not only embody diverse healthcare ecosystems but also offer unique opportunities for customization and sustainable growth. Furthermore, the competitive landscape-bolstered by the innovative efforts of leading companies such as AbbVie Inc., AlgoTherapeutix, Amgen Inc., Array BioPharma Inc. by Pfizer Inc., Artelo Biosciences, Inc., Asahi Kasei Corporation, and other industry giants-reinforces the importance of cross-collaborative research and strategic partnerships in propelling the future of CIPN treatments.

This comprehensive summary provides a clear and actionable roadmap for industry stakeholders, urging them to harness the power of emerging technologies, foster collaborative research, and remain agile in the face of evolving clinical demands. The confluence of meticulous segmentation insights, regional market dynamics, and corporate innovations collectively serves as a testament to the sector's potential to transform patient care and chart new territories in the treatment of chemotherapy induced peripheral neuropathy.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of cancer globally
      • 5.1.1.2. Growing awareness about chemotherapy induced peripheral neuropathy among healthcare providers
      • 5.1.1.3. Surge in government funding for oncology research worldwide
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of drug development processes and research and development activities
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of ergonomic wearables tailored to patients experiencing peripheral neuropathy symptoms
      • 5.1.3.2. Expanding AI technology utilization in developing predictive models for neuropathy risk assessment
    • 5.1.4. Challenges
      • 5.1.4.1. Complexities in neuropathic mechanisms for treatment post-chemotherapy
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment Type: Increasing preferences for anticonvulsants and antidepressants due to their dual function in stabilizing nerve activity
    • 5.2.2. End User: Expanding utilization of CIPN in hospitals
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Non-Pharmacological Treatments
    • 6.2.1. Acupuncture
    • 6.2.2. Physical Therapy
    • 6.2.3. Transcutaneous Electrical Nerve Stimulation
  • 6.3. Pharmacological Treatments
    • 6.3.1. Anticonvulsants
    • 6.3.2. Antidepressants
    • 6.3.3. Opioids

7. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Oral
  • 7.3. Parenteral
    • 7.3.1. Intramuscular
    • 7.3.2. Intravenous
  • 7.4. Topical

8. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Patient Age Group

  • 8.1. Introduction
  • 8.2. Adults
  • 8.3. Geriatrics
  • 8.4. Pediatrics

9. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Therapy Duration

  • 9.1. Introduction
  • 9.2. Long-Term Therapy
  • 9.3. Short-Term Therapy

10. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by End-User

  • 10.1. Introduction
  • 10.2. Home Care Settings
  • 10.3. Hospitals
  • 10.4. Specialty Clinics

11. Americas Chemotherapy Induced Peripheral Neuropathy Treatment Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. NYU Pain Research Center Receives NIH Grant to study chemotherapy-related pain
    • 14.3.2. FDA cleared Artelo Biosciences' IND application for ART26.12
    • 14.3.3. Serpin Pharma and HekaBio's strategic partnership centers on developing SP163M
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. AlgoTherapeutix
  • 3. Amgen Inc.
  • 4. Array BioPharma Inc. by Pfizer Inc.
  • 5. Artelo Biosciences, Inc.
  • 6. Asahi Kasei Corporation
  • 7. Astellas Pharma Inc.
  • 8. Bexion Pharmaceuticals, Inc.
  • 9. Bristol-Myers Squibb Company
  • 10. Eisai Inc.
  • 11. F. Hoffmann-La Roche Ltd
  • 12. GlaxoSmithKline PLC
  • 13. Glenmark Pharmaceuticals Ltd.
  • 14. Grunenthal GmbH
  • 15. Heron Therapeutics, Inc.
  • 16. Ipsen Pharma
  • 17. Kyowa Kirin Co., Ltd.
  • 18. Merck & Co., Inc.
  • 19. Neuralace Medical
  • 20. Novartis AG
  • 21. Regenacy Pharmaceuticals LLC
  • 22. Regeneron Pharmaceuticals, Inc.
  • 23. Sanofi S.A.
  • 24. Serpin Pharma, LLC
  • 25. Takeda Pharmaceutical Company Limited
  • 26. Veloxis Pharmaceuticals, Inc.

LIST OF FIGURES

  • FIGURE 1. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET MULTI-CURRENCY
  • FIGURE 2. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET MULTI-LANGUAGE
  • FIGURE 3. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 4. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 19. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 21. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 27. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ACUPUNCTURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GERIATRICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 72. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 80. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 83. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 95. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 97. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 98. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 100. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 102. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 105. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 106. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 108. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 109. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 110. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 113. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 114. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 116. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 117. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 118. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 121. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 122. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 124. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 125. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 126. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 129. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 130. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 132. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 133. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 134. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 137. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 138. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 140. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 141. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 142. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 145. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 146. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 148. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 150. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 153. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 154. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 156. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 157. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 158. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 159. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 169. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 170. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 172. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 173. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 174. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 175. THAILAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. THAILAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 177. THAILAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 178. THAILAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. THAILAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 180. THAILAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 181. THAILAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 182. THAILAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 183. VIETNAM CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. VIETNAM CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 185. VIETNAM CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 186. VIETNAM CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. VIETNAM CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 188. VIETNAM CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 189. VIETNAM CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 190. VIETNAM CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 200. DENMARK CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. DENMARK CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 202. DENMARK CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 203. DENMARK CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 204. DENMARK CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 205. DENMARK CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 206. DENMARK CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 207. DENMARK CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 208. EGYPT CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. EGYPT CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 210. EGYPT CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 211. EGYPT CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 212. EGYPT CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 213. EGYPT CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 214. EGYPT CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 215. EGYPT CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 216. FINLAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. FINLAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 218. FINLAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 219. FINLAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 220. FINLAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 221. FINLAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 222. FINLAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 223. FINLAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 224. FRANCE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. FRANCE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 226. FRANCE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 227. FRANCE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 228. FRANCE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 229. FRANCE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 230. FRANCE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 231. FRANCE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 232. GERMANY CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. GERMANY CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 234. GERMANY CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 235. GERMANY CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 236. GERMANY CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 237. GERMANY CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 238. GERMANY CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 239. GERMANY CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 240. ISRAEL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. ISRAEL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 242. ISRAEL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 243. ISRAEL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 244. ISRAEL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 245. ISRAEL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 246. ISRAEL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 247. ISRAEL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 248. ITALY CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TR